Atlas Venture is an early-stage venture capital firm specializing in the creation and investment in biotechnology startups. Headquartered in Cambridge, Massachusetts, Atlas has been instrumental in building breakthrough biotech companies for over 30 years.
Atlas Venture employs a seed-led venture creation strategy, partnering with exceptional entrepreneurs and scientists to translate groundbreaking science into life-changing medicines. The firm focuses on building scalable businesses across various disease areas, modalities, and business models, maintaining a disciplined approach to its portfolio.
In December 2024, Atlas Venture announced the closing of its fourteenth fund, raising $450 million to invest in early-stage biotech startups. This fund continues the firm's commitment to collaborating with talented entrepreneurs to found, seed, incubate, and invest in new biotech companies aimed at bringing novel therapeutics to patients.
Team
The Atlas Venture team comprises experienced professionals dedicated to translating high-impact science into medicines for patients. Key members include:
Kevin Bitterman, Ph.D.
Bruce Booth, D.Phil.
Jean-François Formela, M.D.
Michael Gladstone
David Grayzel, M.D.
Jason Rhodes
Notable Investments and Exits
Atlas Venture has a history of successful investments and exits, including:
